CN112336747B - Construction method of nano-engineered neuroblastoma cell - Google Patents
Construction method of nano-engineered neuroblastoma cell Download PDFInfo
- Publication number
- CN112336747B CN112336747B CN202011164557.0A CN202011164557A CN112336747B CN 112336747 B CN112336747 B CN 112336747B CN 202011164557 A CN202011164557 A CN 202011164557A CN 112336747 B CN112336747 B CN 112336747B
- Authority
- CN
- China
- Prior art keywords
- cell
- neuroblastoma
- intra
- nano
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/13—Tumour cells, irrespective of tissue of origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Abstract
The invention discloses a construction method of a nano-engineered neuroblastoma cell. The method mainly utilizes a drug loading technology and a cell membrane display technology to load the contents of neuroblastoma cells into the zirconium-based metal organic framework material and load the neuroblastoma cell membranes onto the surface of the zirconium-based metal organic framework material. The method can destroy the integrity of neuroblastoma cells, avoid the tumor formation of materials in vivo, and simultaneously enable cell membranes and cell contents to play a role in sequence, so that the structural characteristics of the neuroblastoma cells are maintained, the cells are subjected to nanocrystallization, and the biocompatibility is improved. The nano material constructed by the method can promote the regeneration of skin tissues of wounds after burns, can promote the regeneration of hair follicles and restore the original structure of the skin, and is expected to be developed into a novel biological material for more effectively treating serious burns.
Description
Technical Field
The invention belongs to the technical field of material science and provides a construction method of a nano-engineered neuroblastoma cell.
Background
Tumor cells can create immune microenvironment, including tumor-associated macrophages, regulatory T cells, etc., promoting regeneration after injury. Neuroblastoma cells highly express sonic hedgehog, which is essential in the skin for morphogenesis of hair follicles during embryonic development and for regulation of growth and circulation of adult follicles. The sonic hedgehog promotes the transformation of Wnt-activated stem cells and other cells with differentiation potential into dermal papilla, thereby promoting the regeneration of hair follicles. However, only by destroying the integrity of the tumor cells, the regenerative properties of the tumor cells can be utilized without causing in vivo neoplasia.
The zirconium-based metal organic framework (NU-801) has thermal responsiveness, and shows content release under NIR irradiation by wrapping polydopamine on the outside thereof.
The membrane coated nano-particle is a new type of bionic nano-system, which combines the function of the cell membrane and the function flexibility of the synthesized nano-material, can effectively carry out drug delivery and provides a novel treatment method.
NU-801 is used for isolating cell membranes and cytoplasm of neuroblastoma, so that a sequence treatment effect can be achieved, namely, an immune microenvironment beneficial to regeneration is created firstly, and then cell contents are released through NIR irradiation to promote the regeneration of skin and hair follicles, and the in-vivo tumor formation of tumor cells can be avoided. The nanometer material restores the original structure of the skin at the burned part, and is expected to be developed into a novel biological material for more effectively treating serious burn.
Disclosure of Invention
The invention aims to provide a construction method of a nano-engineered neuroblastoma cell, in particular to a construction method of a nano-engineered neuroblastoma cell for promoting hair follicle regeneration after burn, which reduces a cell original structure by a drug loading technology and a cell membrane display technology.
In order to achieve the purpose, the technical scheme provided by the invention is as follows:
loading the contents of the neuroblastoma cells into NU-801 by utilizing a drug loading technology and a cell membrane display technology, loading the neuroblastoma cell membranes on the surface of NU-801, and preparing the nano-engineered neuroblastoma cells.
The invention provides a construction method of a nano-engineered neuroblastoma cell, which is characterized by comprising the following steps: separating cell membranes and cell contents of neuroblastoma by an ultrasonic disruption method and a differential centrifugation method, constructing a zirconium-based metal organic framework NU-801, soaking the NU-801 in a cell content solution, centrifugally purifying, washing with water, covering the cell membranes and polydopamine on the surface of the NU-801 containing the cell contents by a dopamine polymerization process, and centrifugally purifying to obtain the nano-engineered neuroblastoma cells.
Preferably, the nano-engineered neuroblastoma cells gradually degrade under NIR conditions, releasing the cell contents.
Further, the average particle size of the composite nano material is 800 nm-1000 nm.
Further, the specific steps are as follows:
1. isolation of neuroblastoma cell membranes and cell contents:
the neuroblastoma cell suspension was collected in a 50ml centrifuge tube and the cells were broken by ultrasound on ice with the ultrasound set to: amplitude of 35%, total time of 20 minutes, time interval of 5 seconds on 3 seconds off, 4 ℃ 4000rpm centrifugation for 5 minutes, supernatant, 4 ℃ 20000g centrifugation for 30 minutes, precipitation collection as cell content, supernatant 10 ℃ 25000rpm centrifugation for 2 hours, collection of supernatant added to cell content, precipitation as cell membrane.
2. Constructing a zirconium-based metal organic framework NU-801:
1, 4-dibromobenzene (9.44 g, 40 mmol), ethyl acrylate (9 mL, 84.6 mmol), K2CO3（10.35g，75mmol），Pd(OAc)2(0.561 g, 2.5 mmol) and DMF (100mL) were combined in a 250mL round bottom flask. The mixture was stirred at 130 ℃ for 24 hours. Then, it was extracted several times with ethyl acetate and water. The organic phases were combined and over anhydrous MgSO4Drying while distilling the organic solvent under reduced pressure. Thereafter, the mixture was subjected to column chromatography (petroleum/ethyl acetate 4:1 v/v) to obtain diethyl 3,3'- (1, 4-phenylene) (2E, 2' E) -diacrylate as a white powder. Yield: 6g (64%). The white powder (4 g, 14.6 mmol) was suspended in THF (20 mL), H2O (50 mL) and 10m aqueous NaOH (100 mL). The mixture was stirred and heated to reflux for 12 hours, then THF was removed under reduced pressure. Finally, the pH of the solution was adjusted to 3 by using dilute HCl. The solid was collected by filtration, washed with water and dried to give white powder H2PDA；
Organic linker H2PDA (45 mg, 0.21 mmol) and ZrOCl28H 2O (60 mg, 0.186 mmol) in DMF (5 mL) as the main solvent and adding formic acid (0.22 mL) as the conditioning agent, sonicate for 15min, capped vial (15 mL) with a screw cap. The mixture was heated at 70 ℃ for 120 hours. The product was washed 3 times with DMF and acetone, and after centrifugation (10,000 rpm, 15 min) the product was collected by decanting the solvent.
3. Preparation of cell Membrane-coated Metal organic frameworks (Intra @ NU-801@ pD-Mem):
10mL of 10mM Tris-HCl buffer solution (pH 8.5) containing the prepared neuroblastoma cell membranes and 10mg of dopamine hydrochloride was mixed with Intra @ NU-801, vigorously stirred at room temperature for 1h, then purified by centrifugation at 10000 Xg for 20 min, and washed 3 times with deionized water to remove excess cell membranes.
The neuroblastoma cell is a mouse embryo neuroblast cell line Neuro-2a, which is purchased from China Center for Type Culture Collection (CCTCC) with the number of GDC 0162.
The invention has the following advantages and beneficial effects:
1. the neuroblastoma cell line is used as a basic material, so that the generation speed is high, the culture requirement is low, and the biocompatibility is high;
2. the drug loading technology and the cell membrane display technology, the used equipment is simple and the operation is convenient;
3. compared with neuroblastoma cells, the material can sequentially use neuroblastoma cell membranes and cell contents, and sequentially utilize corresponding functions, thereby being more beneficial to regeneration and avoiding in-vivo tumor formation.
Drawings
FIG. 1 is a scanning electron micrograph of Intra @ NU-801@ Mem prepared in example 1.
FIG. 2 is a transmission electron micrograph of Intra @ NU-801@ Mem prepared in example 1.
FIG. 3 is an X-ray diffraction spectrum of NU-801, Intra @ NU-801, and Intra @ NU-801@ pD-Mem prepared in example 1 and comparative example, in which NU-801, Intra @ NU-801, and Intra @ Au-NU-801@ pD-Mem are shown in this order from bottom to top.
FIG. 4 is a Fourier transform infrared spectrum of NU-801, Intra @ NU-801, and Intra @ Au-NU-801@ pD-Mem prepared in example 1 and comparative example, in the order from bottom to top as NU-801, Intra @ NU-801, and Intra @ Au-NU-801@ pD-Mem.
FIG. 5 is a graph showing the particle size analysis of NU-801, Intra @ NU-801, and Intra @ Au-NU-801@ pD-Mem prepared in example 1, wherein NU-801, Intra @ NU-801, and Intra @ Au-NU-801@ pD-Mem are arranged in this order from left to right.
FIG. 6 is a potential analysis diagram of NU-801, Intra @ Au-NU-801@ pD-Mem prepared in example 1, in which NU-801, Intra @ NU-801, and Intra @ Au-NU-801@ pD-Mem are arranged in this order from left to right.
Detailed Description
The invention is further described in detail below with reference to the figures and specific examples.
Example 1
1. Isolation of cell membranes and cell contents of neuroblasts:
the neuroblastoma cell suspension was collected in a 50ml centrifuge tube and the cells were broken by ultrasound on ice with the ultrasound set to: amplitude of 35%, total time of 20 minutes, time interval of 5 seconds on 3 seconds off, 4 ℃ 4000rpm centrifugation for 5 minutes, supernatant, 4 ℃ 20000g centrifugation for 30 minutes, precipitation collection as cell content, supernatant 10 ℃ 25000rpm centrifugation for 2 hours, collection of supernatant added to cell content, precipitation as cell membrane.
2. Constructing a zirconium-based metal organic framework NU-801:
1, 4-dibromobenzene (9.44 g, 40 mmol), ethyl acrylate (9 mL, 84.6 mmol), K2CO3（10.35g，75mmol），Pd(OAc)2(0.561 g, 2.5 mmol) and DMF (100mL) were combined in a 250mL round bottom flask. The mixture was stirred at 130 ℃ for 24 hours. Then, it was extracted several times with ethyl acetate and water. The organic phases were combined and over anhydrous MgSO4Drying while distilling the organic solvent under reduced pressure. Thereafter, the mixture was subjected to column chromatography (petroleum/ethyl acetate 4:1 v/v) to obtain diethyl 3,3' - (1, 4) as a white powder-phenylene) (2E, 2' E) -diacrylate. Yield: 6g (64%). The white powder (4 g, 14.6 mmol) was suspended in THF (20 mL), H2O (50 mL) and 10m aqueous NaOH (100 mL). The mixture was stirred and heated to reflux for 12 hours, then THF was removed under reduced pressure. Finally, the pH of the solution was adjusted to 3 by using dilute HCl. The solid was collected by filtration, washed with water and dried to give white powder H2PDA；
Organic linker H2PDA (45 mg, 0.21 mmol) and ZrOCl28H 2O (60 mg, 0.186 mmol) in DMF (5 mL) as the main solvent and adding formic acid (0.22 mL) as the conditioning agent, sonicate for 15min, capped vial (15 mL) with a screw cap. The mixture was heated at 70 ℃ for 120 hours. The product was washed 3 times with DMF and acetone, and after centrifugation (10,000 rpm, 15 min) the product was collected by decanting the solvent.
3. Preparation of cell Membrane-coated Metal organic frameworks (Intra @ NU-801@ pD-Mem):
10mL of 10mM Tris-HCl buffer (pH 8.5) containing 500. mu.g of the prepared neuroblastoma cell membranes and 10mg of dopamine hydrochloride was mixed with Intra @ NU-801, vigorously stirred at room temperature for 1h, then purified by centrifugation at 10000 Xg for 20 min, and washed 3 times with deionized water to remove excess cell membranes.
Example 2
1. Isolation of cell membranes and cell contents of neuroblasts:
the neuroblastoma cell suspension was collected in a 50ml centrifuge tube and the cells were broken by ultrasound on ice with the ultrasound set to: amplitude of 35%, total time of 20 minutes, time interval of 5 seconds on 3 seconds off, 4 ℃ 4000rpm centrifugation for 5 minutes, supernatant, 4 ℃ 20000g centrifugation for 30 minutes, precipitation collection as cell content, supernatant 10 ℃ 25000rpm centrifugation for 2 hours, collection of supernatant added to cell content, precipitation as cell membrane.
2. Constructing a zirconium-based metal organic framework NU-801:
1, 4-dibromobenzene (9.44 g, 40 mmol), ethyl acrylate (9 mL, 84.6 mmol), K2CO3（10.35g，75mmol），Pd(OAc)2(0.561 g, 2.5 mmol) and DMF (100mL) were combined in a 250mL round bottom flask. The mixture was stirred at 130 ℃ for 24 hours. Then, it was extracted several times with ethyl acetate and water. The organic phases were combined and over anhydrous MgSO4Drying while distilling the organic solvent under reduced pressure. Thereafter, the mixture was subjected to column chromatography (petroleum/ethyl acetate 4:1 v/v) to obtain diethyl 3,3'- (1, 4-phenylene) (2E, 2' E) -diacrylate as a white powder. Yield: 6g (64%). The white powder (4 g, 14.6 mmol) was suspended in THF (20 mL), H2O (50 mL) and 10m aqueous NaOH (100 mL). The mixture was stirred and heated to reflux for 12 hours, then THF was removed under reduced pressure. Finally, the pH of the solution was adjusted to 3 by using dilute HCl. The solid was collected by filtration, washed with water and dried to give white powder H2PDA；
Organic linker H2PDA (45 mg, 0.21 mmol) and ZrOCl28H 2O (60 mg, 0.186 mmol) in DMF (5 mL) as the main solvent and adding formic acid (0.22 mL) as the conditioning agent, sonicate for 15min, capped vial (15 mL) with a screw cap. The mixture was heated at 70 ℃ for 120 hours. The product was washed 3 times with DMF and acetone, and after centrifugation (10,000 rpm, 15 min) the product was collected by decanting the solvent.
3. Preparation of cell Membrane-coated Metal organic frameworks (Intra @ NU-801@ pD-Mem):
10mL of 10mM Tris-HCl buffer (pH 8.5) containing 1000. mu.g of prepared neuroblastoma cell membranes and 10mg of dopamine hydrochloride was mixed with Intra @ NU-801, vigorously stirred at room temperature for 1h, then purified by centrifugation at 10000 Xg for 20 min, and washed 3 times with deionized water to remove excess cell membranes.
Example 3
1. Isolation of cell membranes and cell contents of neuroblasts:
the neuroblastoma cell suspension was collected in a 50ml centrifuge tube and the cells were broken by ultrasound on ice with the ultrasound set to: amplitude of 35%, total time of 20 minutes, time interval of 5 seconds on 3 seconds off, 4 ℃ 4000rpm centrifugation for 5 minutes, supernatant, 4 ℃ 20000g centrifugation for 30 minutes, precipitation collection as cell content, supernatant 10 ℃ 25000rpm centrifugation for 2 hours, collection of supernatant added to cell content, precipitation as cell membrane.
2. Constructing a zirconium-based metal organic framework NU-801:
1, 4-dibromobenzene (9.44 g, 40 mmol), ethyl acrylate (9 mL, 84.6 mmol), K2CO3（10.35g，75mmol），Pd(OAc)2(0.561 g, 2.5 mmol) and DMF (100mL) were combined in a 250mL round bottom flask. The mixture was stirred at 130 ℃ for 24 hours. Then, it was extracted several times with ethyl acetate and water. The organic phases were combined and over anhydrous MgSO4Drying while distilling the organic solvent under reduced pressure. Thereafter, the mixture was subjected to column chromatography (petroleum/ethyl acetate 4:1 v/v) to obtain diethyl 3,3'- (1, 4-phenylene) (2E, 2' E) -diacrylate as a white powder. Yield: 6g (64%). The white powder (4 g, 14.6 mmol) was suspended in THF (20 mL), H2O (50 mL) and 10m aqueous NaOH (100 mL). The mixture was stirred and heated to reflux for 12 hours, then THF was removed under reduced pressure. Finally, the pH of the solution was adjusted to 3 by using dilute HCl. The solid was collected by filtration, washed with water and dried to give white powder H2PDA；
Organic linker H2PDA (45 mg, 0.21 mmol) and ZrOCl28H 2O (60 mg, 0.186 mmol) in DMF (5 mL) as the main solvent and adding formic acid (0.22 mL) as the conditioning agent, sonicate for 15min, capped vial (15 mL) with a screw cap. The mixture was heated at 70 ℃ for 120 hours. The product was washed 3 times with DMF and acetone, and after centrifugation (10,000 rpm, 15 min) the product was collected by decanting the solvent.
3. Preparation of cell Membrane-coated Metal organic frameworks (Intra @ NU-801@ pD-Mem):
10mL of 10mM Tris-HCl buffer (pH 8.5) containing 2000. mu.g of prepared neuroblastoma cell membranes and 10mg of dopamine hydrochloride was mixed with Intra @ NU-801, vigorously stirred at room temperature for 1h, then purified by centrifugation at 10000 Xg for 20 min, and washed 3 times with deionized water to remove excess cell membranes.
Claims (4)
1. A method for constructing a nano-engineered neuroblastoma cell, comprising: separating cell membranes and cell contents of neuroblastoma by an ultrasonic disruption method and a differential centrifugation method, constructing a zirconium-based metal organic framework NU-801, soaking the NU-801 in a cell content solution, centrifugally purifying, washing with water, covering the cell membranes and polydopamine on the surface of the NU-801 containing the cell contents by a dopamine polymerization process, and centrifugally purifying to obtain the nano-engineered neuroblastoma cells.
2. The method of claim 1, wherein the method comprises the steps of: under NIR conditions, the nano-engineered neuroblastoma cells gradually degrade, releasing the cell contents.
3. The method of claim 1 or 2, wherein the method comprises the steps of: the method comprises the following specific steps:
s1: isolation of neuroblastoma cell membranes and cell contents:
the neuroblastoma cell suspension was collected in a 50ml centrifuge tube and the cells were broken by ultrasound on ice with the ultrasound set to: amplitude is 35%, total time is 20 minutes, and interval time is 5 seconds, and the switch is on and off for 3 seconds; centrifuging at 4000rpm at 4 deg.C for 5min by differential centrifugation, collecting supernatant, centrifuging at 20000g at 4 deg.C for 30 min, collecting precipitate as cell content, centrifuging at 25000rpm at 10 deg.C for 2 hr, collecting supernatant, adding into cell content, and precipitating to obtain cell membrane;
s2: constructing a zirconium-based metal organic framework NU-801:
1, 4-dibromobenzene, ethyl acrylate and K2CO，Pd(OAc)2And DMF in a 250mL round bottom flask; the mixture was stirred at 130 ℃ for 24 hours; then, it was extracted several times with ethyl acetate and water; the organic phases were combined and over anhydrous MgSO4Drying while reducing pressureDistilling the organic solvent; thereafter, the mixture was subjected to column chromatography, petroleum/ethyl acetate 4:1 v/v, to obtain diethyl 3,3'- (1, 4-phenylene) (2E, 2' E) -diacrylate as a white powder; suspending the white powder in THF, H2O and 10m NaOH aqueous solution; the mixture was stirred and heated to reflux for 12 hours, then THF was removed under reduced pressure; finally, the pH of the solution was adjusted to 3 by using dilute HCl; the solid was collected by filtration, washed with water and dried to give white powder H2PDA；
Organic linker H2PDA and ZrOCl28H 2O mixture was dissolved in DMF as the main solvent and added formic acid as the conditioning agent and sonicated for 15 minutes, closing a vial with a screw cap; heating the mixture at 70 ℃ for 120 hours; the product was washed 3 times with DMF and acetone, and collected by decanting the solvent after centrifugation;
s3: preparation of NU-801 Encapsulated cell content Intra @ NU-801:
immersing NU-801 in 15ml of an aqueous solution containing cell contents for 12 hours; separating the Intra @ NU-801 from the solution by centrifugation, followed by washing with water and then storing in water;
s4: preparation of cell membrane-wrapped Metal-organic framework Intra @ NU-801@ pD-Mem:
mixing 10mL of 10mM Tris-HCl buffer solution pH 8.5 containing the prepared neuroblastoma cell membranes and 10mg of dopamine hydrochloride with Intra @ NU-801, vigorously stirring at room temperature for 1h, then centrifuging at 10000 Xg for 20 min for purification, and washing with deionized water 3 times to remove excess cell membranes; intra @ NU-801@ pD-Mem shows membrane proteins of murine embryonic neuroblastoma.
4. The method of claim 3, wherein the method comprises the steps of: the neuroblastoma cell is a mouse embryo neuroblast cell line Neuro-2a, purchased from China Center for Type Culture Collection (CCTCC) with the number of GDC 0162.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011164557.0A CN112336747B (en) | 2020-10-27 | 2020-10-27 | Construction method of nano-engineered neuroblastoma cell |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011164557.0A CN112336747B (en) | 2020-10-27 | 2020-10-27 | Construction method of nano-engineered neuroblastoma cell |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112336747A CN112336747A (en) | 2021-02-09 |
| CN112336747B true CN112336747B (en) | 2022-07-05 |
Family
ID=74360264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011164557.0A Active CN112336747B (en) | 2020-10-27 | 2020-10-27 | Construction method of nano-engineered neuroblastoma cell |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112336747B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106139144A (en) * | 2016-06-27 | 2016-11-23 | 华中科技大学同济医学院附属协和医院 | A kind of hyaluronic acid decorated golden Nano carbon balls with synergistic antitumor characteristic and preparation method and application |
| WO2018162676A1 (en) * | 2017-03-08 | 2018-09-13 | Université De Strasbourg | DISINTEGRATABLE POROUS ORGANOSILICA OR ORGANOMETALOXIDE NANOPARTICLES AND USES THEREOF AS VEHICLE FOR CONTROLLED DELIVERY OF siRNA |
| CN108524934A (en) * | 2018-05-16 | 2018-09-14 | 武汉大学 | A kind of nano medicament carrying system and the preparation method and application thereof |
| CN109498654A (en) * | 2018-11-20 | 2019-03-22 | 米新亮 | A kind of cell package system and its assemble method |
| CN111346236A (en) * | 2018-12-21 | 2020-06-30 | 中国医学科学院生物医学工程研究所 | Polydopamine nanoparticle loaded with tumor antigen as well as preparation method and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10188508B2 (en) * | 2015-04-24 | 2019-01-29 | Wisconsin Alumni Research Foundation | Bioengineered vocal fold mucosa for functional voice restoration |
-
2020
- 2020-10-27 CN CN202011164557.0A patent/CN112336747B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106139144A (en) * | 2016-06-27 | 2016-11-23 | 华中科技大学同济医学院附属协和医院 | A kind of hyaluronic acid decorated golden Nano carbon balls with synergistic antitumor characteristic and preparation method and application |
| WO2018162676A1 (en) * | 2017-03-08 | 2018-09-13 | Université De Strasbourg | DISINTEGRATABLE POROUS ORGANOSILICA OR ORGANOMETALOXIDE NANOPARTICLES AND USES THEREOF AS VEHICLE FOR CONTROLLED DELIVERY OF siRNA |
| CN108524934A (en) * | 2018-05-16 | 2018-09-14 | 武汉大学 | A kind of nano medicament carrying system and the preparation method and application thereof |
| CN109498654A (en) * | 2018-11-20 | 2019-03-22 | 米新亮 | A kind of cell package system and its assemble method |
| CN111346236A (en) * | 2018-12-21 | 2020-06-30 | 中国医学科学院生物医学工程研究所 | Polydopamine nanoparticle loaded with tumor antigen as well as preparation method and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| RGD肽与可剪切PEG共修饰脂质体的构建及体外抗肿瘤作用评价;魏霖;《中国优秀博硕士学位论文全文数据库(硕士)医药卫生科技辑》;20131215(第S2期);E072-6 * |
| Thermal Stimuli-Triggered Drug Release from a Biocompatible Porous Metal–Organic Framework;Ke Jiang等;《Chemistry-A European Journal》;20170706;第23卷(第42期);10215-10221 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112336747A (en) | 2021-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Silva et al. | Ionic liquids in the processing and chemical modification of chitin and chitosan for biomedical applications | |
| EP3354665B1 (en) | Modified alginates for cell encapsulation and cell therapy | |
| CN110330004B (en) | Method for regulating morphology of hydroxyapatite micro-nano material by using phosphorus source | |
| WO2020199349A1 (en) | Nano pore channel-type natural slow and controlled release carrier material and preparation method therefor | |
| JP2019510586A (en) | Stem cells, bone, tissues and nerve scaffolds obtained from discrete carbon nanotubes | |
| CN104927319B (en) | A kind of preparation method of hydroxyapatite grafted polylactic acid | |
| CN109293976A (en) | A kind of preparation method of Porous Chitosan Microspheres | |
| TW202144465A (en) | New method of synthesis of chitosan derivatives and uses thereof | |
| Caro-León et al. | Production and characterization of supercritical CO2 dried chitosan nanoparticles as novel carrier device | |
| CN112336747B (en) | Construction method of nano-engineered neuroblastoma cell | |
| CN109045298A (en) | A kind of preparation method of the photodynamic hypericin-folic acid-fluorinated graphene polymer nanocomposites of targeting-photo-thermal- | |
| CN110327984B (en) | Pt @ PCN-224 photocatalyst for preparing artemisinin from dihydroarteannuic acid and preparation method thereof | |
| CN110408187B (en) | Injectable chitosan-based hydrogel with self-repairing property and high mechanical strength, and preparation method and application thereof | |
| Abbas | Chitosan for biomedical applications | |
| WO2020259018A1 (en) | Self-assembled catalase nanoparticle, and preparation method therefor and use thereof | |
| CN113908137B (en) | Preparation method of hard-core soft-membrane type nano sustained-release drug delivery system for injection | |
| CN113599538B (en) | Teriparatide supermolecule slow-release nanoparticle and preparation method thereof | |
| CN113912653B (en) | Method for improving bulk density of beta-nicotinamide mononucleotide crystalline powder | |
| CN105311642A (en) | Pectin anticancer prodrug synthesis process | |
| CN110302422B (en) | Temperature-sensitive hydrogel modified by calcium magnesium silicate nano hollow microspheres and preparation method and application thereof | |
| CN101314058A (en) | Modification method for animal skin collagen | |
| CN109568666B (en) | Gd:Fe3O4Method for repairing spinal nerve injury by using @ RA composite nano molecule and MRI (magnetic resonance imaging) contrast method | |
| CN113633624A (en) | Preparation method of alginate-magnetic chitosan microspheres with core-shell structures | |
| CN101422460B (en) | Preparation method of FK506 slow-release film for repairing nerve damage | |
| CN109999009B (en) | Oral sustained-release preparation of antitumor drug and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |